Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the best cheap biotech stocks to buy now. On February 27, Wells Fargo cut the price target on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to $38 from $45 while maintaining an Overweight rating on the shares. The firm stated that, given 2026 guidance, it appears that the GTx launch reset post safety events could take longer than it expected, and thus it adjusted its ELEVIDYS numbers, arriving at a new price target. That said, Wells Fargo anticipates the siRNA ...